EXTON, PA — West Pharmaceutical Services Inc. (NYSE: WST) reported fourth-quarter net sales of $805.0 million and full-year net sales of $3.074 billion for 2025, both increases from the prior year, the company announced.
Fourth-quarter net sales rose 7.5% year over year, with organic growth of 3.3%. Diluted earnings per share for the quarter were $1.82, up 2.2%, while adjusted diluted EPS increased 12.1% to $2.04.
For the full year, net sales increased 6.3%, with organic growth of 4.3%. Diluted EPS rose 1.5% to $6.79, and adjusted diluted EPS increased 8.0% to $7.29.
Operating cash flow for 2025 totaled $754.8 million, up 15.5%. Capital expenditures were $285.9 million, resulting in free cash flow of $468.9 million, an increase of 69.6%.
During 2025, the company repurchased 552,593 shares for $134.0 million at an average price of $242.55 per share.
“Our strong finish to 2025 was a result of the team’s relentless execution of our growth strategy,” President, Chief Executive Officer and Chair Eric M. Green said in a statement. “Our performance in the quarter was led by our High-Value Product Components business in our Proprietary Products Segment, enabling us to deliver double-digit adjusted earnings per share growth. We expect positive momentum to continue in 2026, which will be a key year of execution and operational excellence to drive sustainable growth and create value for our patients, customers and shareholders.”
In the fourth quarter, the Proprietary Products segment reported net sales of $661.8 million, up 7.8%. High-Value Product Components sales increased 20.3% to $389.8 million.
The Contract-Manufactured Products segment reported fourth-quarter net sales of $143.2 million, up 6.2%.
For 2026, West expects full-year net sales between $3.215 billion and $3.275 billion and adjusted diluted EPS between $7.85 and $8.20.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.